Compare CHR & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHR | ZNTL |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.9M | 162.5M |
| IPO Year | N/A | 2020 |
| Metric | CHR | ZNTL |
|---|---|---|
| Price | $1.44 | $2.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $5.87 |
| AVG Volume (30 Days) | 151.9K | ★ 2.5M |
| Earning Date | 07-30-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 96.06 | N/A |
| Revenue | ★ $147,134,000.00 | $26,865,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.22 | $1.01 |
| 52 Week High | $141.71 | $3.95 |
| Indicator | CHR | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 52.39 | 48.66 |
| Support Level | $1.48 | $2.65 |
| Resistance Level | $1.63 | $3.00 |
| Average True Range (ATR) | 0.15 | 0.34 |
| MACD | -0.08 | -0.12 |
| Stochastic Oscillator | 3.93 | 5.25 |
Cheer Holding Inc is a provider of next generation mobile internet infrastructure and platform services in China. It is engaged in building a digital ecosystem that integrates platforms, applications, technology, and industry into a cohesive system, thereby creating a new, open business environment that leverages AI technology. Its portfolio includes various products and services, such as Polaris Intelligent Cloud, CHEERS Telepathy, CHEERS Open Platform, CHEERS Video, CHEERS e-Mall, CheerReal, CheerCar, CheerChat, CHEERS Fresh Group-Buying E-commerce Platform, Digital Innovation Research Institute, CHEERS Livestreaming, variety show series, IP short video matrix, and more.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.